STAAR Surgical Company (STAA)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$23.47-0.47%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
Intact: The reason to own it still holds.
STAAR Surgical grew revenue from $42.6M to $93.5M in one year. Operating income improved from -$57.4M to $8.0M in the same period. Net income turned positive at $5.2M, showing a strong recovery. Management is focused on growth and cost control.
The company still faces high risk with a 58.4 PE and negative free cash flow yield. Recent share price fell 18% from highs, reflecting market doubts. Profitability gains may not sustain if growth slows or costs rise.
The stock trades about 26% above our $17.72 fair value, with analysts expecting 6.7% revenue growth. Our fair value is 44% below the Street median, indicating the market prices in stronger growth than we see.
Breaks if: Net income falls below $5.2M in 2026-Q1
Breaks if: Operating income falls below $8.0M in 2026-Q1
Breaks if: Revenue falls below $93.5M in 2026-Q1
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company has shown strong revenue growth and improving profit margins, but it is still loss-making and management has been volatile.
The market seems to have priced in a justified valuation, but it is considered expensive compared to peers. There is a slight expectations gap, indicating that the market may not fully reflect the potential for continued growth.
Management is focused on accelerating revenue growth and expanding profit margins, which they have been successfully achieving. However, the company remains at risk due to its high volatility and the potential for earnings misses.
The future performance hinges on management's ability to maintain revenue growth and profit expansion, as well as external factors like sector performance and economic conditions. Key triggers include guidance changes and the performance of major healthcare peers.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a positive outlook. The company plans to maintain disciplined capital allocation and cost management. It also aims to accelerate revenue growth in key markets. There are no new threats identified at this time.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Over the next 1 to 3 years, STAA's trajectory will depend on its execution in growth and profitability amidst a challenging market backdrop. Not investment advice.